Fertility and Sterility
Volume 93, Issue 6 , Pages 1997-2003, April 2010

Levonorgestrel effects on serum androgens, sex hormone–binding globulin levels, hair shaft diameter, and sexual function

  • George Kovalevsky, M.D.

      Affiliations

    • Reproductive Associates of Delaware, Newark, Delaware
    • Corresponding Author InformationReprint requests: George A. Kovalevsky, M.D., 4735 Ogletown-Stanton Road, MAP 2, Suite 3217, Newark, Delaware 19713 (FAX: 302-623-4241).
  • ,
  • Susan A. Ballagh, M.D.

      Affiliations

    • CONRAD Clinical Research Center, Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, Virginia
  • ,
  • Frank Z. Stanczyk, Ph.D.

      Affiliations

    • Department of Obstetrics and Gynecology, Keck School of Medicine, University of Southern California, Los Angeles, California
  • ,
  • Jennifer Lee, B.S.

      Affiliations

    • CONRAD Clinical Research Center, Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, Virginia
  • ,
  • Joann Cooper, B.S.

      Affiliations

    • CONRAD Clinical Research Center, Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, Virginia
  • ,
  • David F. Archer, M.D.

      Affiliations

    • CONRAD Clinical Research Center, Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, Virginia

Received 13 August 2008; received in revised form 29 October 2008; accepted 18 December 2008. published online 27 April 2009.

Objective

To determine the effects of levonorgestrel (LNG) on serum androgens, sex hormone–binding globulin (SHBG), hair shaft diameter, and sexual function in women.

Design

Substudy of a prospective randomized double-blind study in women using an LNG SC implant (LNG-SI), who were treated with doxycycline or placebo.

Setting

Medical school department of obstetrics and gynecology.

Patient(s)

Forty women were enrolled; 36 completed the study.

Intervention(s)

Participants were randomized to doxycycline 20 mg or an identical placebo orally twice a day after LNG-SI insertion.

Main Outcome Measure(s)

Serum levels of total T (TT), free T (FT), androstenedione (A), dehydroepiandrosterone sulfate (DHEAS), dihydrotestosterone (DHT), androstanediol glucuronide (AG), SHBG, and LNG; hair shaft diameter; and sexual function using the Brief Index of Sexual Function for Women and the Arizona Sexual Experiences Scale were assessed.

Result(s)

Serum TT, A, DHT, DHEAS, and SHBG declined after LNG-SI insertion. No changes were found in FT, AG, hair shaft diameter, or sexual function. Serum LNG correlated with SHBG levels. There were no differences between the placebo and doxycycline groups.

Conclusion(s)

LNG reduced serum TT, A, DHT, DHEAS, and SHBG but had no effect on sexual function or markers of androgen bioactivity.

Key Words: Levonorgestrel subcutaneous implant, sex hormone–binding globulin, serum androgens, hair shaft diameter, sexual function, testosterone

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 G.K. has nothing to disclose. S.A.B. has nothing to disclose. F.Z.S. has nothing to disclose. J.L. has nothing to disclose. J.C. has nothing to disclose. D.F.A. has consulted for Abbott Laboratories, Agile Therapeutics, Bayer Healthcare, Berlex, ConCert Pharmaceutical, Novo Nordisk, Radius, Schering Plough, Warner Chilcott, and Wyeth Laboratories; received research support from Bayer, Duramed, Organon-Schering Plough, Solvay, Warner Chilcott, and Wyeth; and received lecture fees from Novo Nordisk, Organon-Schering Plough, Solvay, Upsher-Smith, and Wyeth.

 This study was supported by National Institute of Child Health and Human Development grant no. R01 HD43175-01.

PII: S0015-0282(08)04798-5

doi:10.1016/j.fertnstert.2008.12.095

Fertility and Sterility
Volume 93, Issue 6 , Pages 1997-2003, April 2010